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What is already known about the topic?
•• The use of outcome assessment tools is important to measure quality and effectiveness of care.
•• The population of children requiring paediatric palliative care services is diverse.
•• There are no outcome assessment tools validated specifically for use within paediatric palliative care.
What this paper adds?
•• This is the first review to systematically identify existing health-related quality-of-life outcome measures for use in pae-
diatric palliative care.
•• The paper finds that there is currently no ‘ideal’ outcome assessment tool for use in paediatric palliative care.
Health-related quality-of-life outcome 
measures in paediatric palliative care: 
A systematic review of psychometric 
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Abstract
Background: The number of children worldwide requiring palliative care services is increasing due to advances in medical care and 
technology. The use of outcome measures is important to improve the quality and effectiveness of care.
Aim: To systematically identify health-related quality-of-life outcome measures that could be used in paediatric palliative care and 
examine their feasibility of use and psychometric properties.
Design: A systematic literature review and analysis of psychometric properties.
Data sources: PsychInfo, Medline and EMBASE were searched from 1 January 1990 to 10 December 2014. Hand searches of the 
reference list of included studies and relevant reviews were also performed.
Results: From 3460 articles, 125 papers were selected for full-text assessment. A total of 41 articles met the eligibility criteria 
and examined the psychometric properties of 22 health-related quality-of-life measures. Evidence was limited as at least half of the 
information on psychometric properties per instrument was missing. Measurement error was not analysed in any of the included 
articles and responsiveness was only analysed in one study. The methodological quality of included studies varied greatly.
Conclusion: There is currently no ‘ideal’ outcome assessment measure for use in paediatric palliative care. The domains of generic 
health-related quality-of-life measures are not relevant to all children receiving palliative care and some domains within disease-
specific measures are only relevant for that specific population. Potential solutions include adapting an existing measure or developing 
more individualized patient-centred outcome and experience measures. Either way, it is important to continue work on outcome 
measurement in this field.
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Implications for practice, theory or policy
•• As with adults, both outcome and experience measures are important to achieve and maintain best care for children and 
young people.
•• Understanding a child or young person’s own goals for care and treatment – alongside more standardized outcomes – is 
likely to be most valuable.
Background
Palliative care for children begins at diagnosis and encom-
passes children with a variety of life-limiting and life-
threatening conditions. Life-limiting conditions are 
diseases where there is no reasonable hope of cure and that 
will ultimately be fatal.1 Life-threatening conditions are 
those where curative treatment may be possible but can 
fail, for example, cancer. Worldwide, more children are 
living longer with such conditions due to advances in med-
ical care. Paediatric palliative care (PPC) is about helping 
children and their families deal with their medical condi-
tion, while enabling them to live life to the fullest.2 
Palliative care for children and young people (CYP) is an 
active and total approach to care, and begins at the point of 
diagnosis, throughout the child’s life, death and beyond.3 
The scope of PPC is broad and PPC services care for CYP 
with a wide variety of illnesses, many of which are 
extremely rare.3,4 Children can be receiving care from 
these services for many years and therefore it is imperative 
to ensure that they are supported to live life to their fullest 
potential.
Health-related quality of life (HRQOL) has been 
described as a subjective, multidimensional and dynamic 
construct that comprises physical, psychological and social 
functioning.5 HRQOL measurement instruments must 
consist of physical, social and mental health dimensions as 
delineated by the World Health Organization (WHO).6 
Given that one of the goals of PPC is to improve HRQOL, 
service providers, researchers, fundraisers and policy mak-
ers will want to measure HRQOL and determine the effec-
tiveness of services in achieving this.
There are no paediatric HRQOL measures that have 
been successfully validated for use within PPC. One study 
did attempt to validate the well-used Pediatric Quality of 
Life 4.0 measure in children with a variety of life-limiting 
conditions. However, the study found that the instrument 
did not have valid psychometric properties for use within 
this population.7 Therefore, within PPC, two possibilities 
exist: devising a completely new HRQOL instrument, or 
revising and validating an existing one. A review of exist-
ing HRQOL measures is essential prior to deciding which 
course of action to take.
The aim of this systematic literature review is to exam-
ine the measurement properties of existing HRQOL instru-
ments for use in those up to 18 years old. It will also assess 
the feasibility of the measures being used in the CYP pallia-
tive care population in terms of completion time, response 
options, recall period, format, domains and whether the 
measure is parent, professional or self-completed.
Methods
This systematic literature review was performed in accord-
ance with Preferred Reporting Items for Systematic 
Reviews and Meta-analyses (PRISMA) guidelines.8
Identification of studies
PsychInfo, Medline and EMBASE were searched from 1 
January 1990 to 10 December 2014. Experts in the field 
were asked to suggest any further measures. The search 
terms used included keywords such as child, adolescent 
and teenager in combination with terms used to find stud-
ies on measurement properties of HRQOL measures.9,10 
Language restriction to the English language was applied 
due to practical constraints within the research team. 
Reference lists of included articles were also searched for 
further publications. Box 1 shows the search strategy used.
Box 1. Search strategy.
1.  patient reported outcomes.ti,ab.
(6383)
2. quality of life.ti.ab.(266914)
3. health status.ti,ab.(175146)
4. global health.ti.ab.(53851)
5.  health related quality of life.ti.ab.
(53363)
6.  outcome measurement.ti.ab.
(26871)
7.  1 or 2 or 3 or 4 or 5 or 
6(491494)
8. classical test theory.ti.ab.(1460)
9. validity.ti.ab(205095)
10. reliability.ti.ab.(162542)
11. content validity.ti.ab.(16710)
12.  confirmatory factor analysis.
ti.ab.(17892)
13.  exploratory factor analysis.ti.ab.
(13537)
14.  internal consistency.ti.ab.
(39236)
15. test-retest.ti.ab.(30481)
16. psychometr*.ti.ab.(66358)
17. known group.ti.ab.(108113)
18. Rasch.ti.ab.(5442)
19. DIF.ti.ab.(2784)
20.  8 or 9 or 10 or 11 or 12 or 13 
or 14 or 15 or 16 or 17 or 18 
or 19 or 20 or 21 (998874)
21. child*.ti.ab.(1286933)
22. neonat*.ti.ab.(185516)
23. adolescent*.ti.ab.(308550)
24. pediatric*.ti.ab.(213646)
25. paediatric*.ti.ab.(48497)
26.  23 or 24 or 25 or 26 or 27 
(1715918)
27. 7 and 22 and 28 (7138)
28.  29 limited to Human and English 
Language and Age Groups All 
Child Age 0–18 years (4849)
29. Duplicates removed 1398
30. Total 3451
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Inclusion/exclusion criteria
A study was included if it met the following inclusion 
criteria:
•• Full-text article;
•• Written in the English language;
•• Examining one or more measurement properties of 
an instrument that measured physical, mental and 
social aspects of HRQOL as delineated by WHO;6
•• The study population were under 18 years old;
•• The measure was generic or disease specific;
•• Disease-specific instruments had to assess HRQOL 
in an illness considered to be life-limiting or 
life-threatening;3,4
•• Studies of generic measures were included only if 
some or all of the population in the study had a life-
limiting illness;
•• Included measures could be completed by the CYP, 
parent or clinician.
Study selection
The results of the search were thoroughly checked and full 
manuscripts of all studies whose title/abstract seemed to 
meet the selection criteria were retrieved. Independent 
reviewers (L.H.C. and G.L.) examined these full-text arti-
cles and made the final decision as to whether they were 
included.
Data extraction
The methodological quality of included studies was rated 
using the COnsensus based Standards for the selection of 
health Measurement INstruments (COSMIN) checklist.11 
This checklist contains nine boxes, each dealing with one 
measurement property. There are 5–18 items per box (98 
items in total) that can be used to assess whether a study 
on a specific measurement property meets the standard for 
good methodological quality. The checklist evaluates the 
following measurement properties: internal consistency, 
reliability, measurement error, content validity, construct 
validity (structural validity, hypothesis testing, cross-cul-
tural validity), criterion validity and responsiveness. 
There are three additional boxes: one to assess the meth-
odological quality of studies on interpretability, one to 
assess the generalizability of results and one that includes 
extra methodological standards for studies that use item 
response theory (IRT; 12 boxes in total). Each item is 
scored on a 4-point rating scale (poor, fair, good and 
excellent).12 An overall score for the methodological qual-
ity of a study is determined for each measurement prop-
erty separately, by taking the lowest rating of any item in 
a box (worst score counts).11
Box 2 gives definitions of these measurement properties.
Synthesis of results
To summarize the evidence of measurement properties of 
each included instrument, the results were combined. The 
number and methodological quality of the studies were 
taken into account, along with the consistency of results. A 
method similar to that proposed by the Cochrane Back 
Review Group was used (Table 1).17
The overall rating of each measurement property is 
‘positive’, ‘negative’ or ‘indeterminate’, accompanied by 
levels of evidence. These criteria were originally meant for 
systematic reviews of clinical trials but have been used in 
reviews on measurement properties.12 To assess whether 
results of measurement properties were positive, negative 
or indeterminate, criteria based on Terwee et al.18 were 
used (Table 2).
This assessment of measurement properties was then 
looked at alongside the feasibility of each measure being 
used in PPC in terms of completion time, response options, 
recall period, format and domains.
Research ethics committee/institutional review board 
(IRB) approvals were not required as this was a systematic 
review of pre-existing evidence.
Results
Paper selection
A total of 3451 articles were found using the search strat-
egy and a further 9 were found via reference searching. A 
total of 125 of these were selected for full-text review 
based on title and abstract. A total of 41 were selected to be 
included in the review. Figure 1 shows a flow chart of the 
article selection process, and Table 3 shows the general 
characteristics of included studies.
Box 2. Definitions of measurement properties.
Reliability
This term is used twice – as a term for the domain and also 
as the term for the measurement property.13,14 Defined as 
the degree to which measurement is free from measurement 
error. Includes internal consistency, reliability (test–retest, 
inter-rater, intra-rater) and measurement error.12,13,15
Validity
The degree to which a tool measures the construct it claims 
to measure. Includes content validity, criterion validity and 
construct validity.13,15
Responsiveness
The ability of an instrument to detect change over time in 
the construct being measured.16
Interpretability
The degree to which qualitative meaning can be assigned 
to the quantitative scores or change in scores of an 
instrument. This is an important property of an instrument 
but not a measurement property.13
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Table 1. Levels of evidence for overall quality of measurement property.
Level Rating Criteria
Strong +++ or −−− Consistent findings in multiple studies of good methodological quality OR in one study of 
excellent methodological quality
Moderate ++ or −− Consistent findings in multiple studies of fair methodological quality OR in one study of 
good methodological quality
Limited + or − One study of fair methodological quality
Conflicting ± Conflicting findings
Unknown ? Only studies of poor methodological quality
Source: Tulder et al.17
+: positive results; −: negative results.
Table 2. Quality criteria for measurement properties.
Property Rating Quality criteria
Reliability
 Internal consistency + (Sub)scale unidimensional AND Cronbach’s alpha(s) ⩾0.70
? Dimensionality not known OR Cronbach’s alpha not determined
− (Sub)scale not unidimensional OR Cronbach’s alpha < 0.7
 Measurement error + MIC > SDC OR MIC outside the LOA
? MIC not defined
− MIC ⩽ SDC OR MIC equals or inside LOA
 Reliability + ICC/weighted kappa ⩾ 0.70 OR Pearson’s r ⩾ 0.80
? Neither ICC/weighted kappa nor Pearson’s r determined
− ICC/weighted kappa < 0.70 OR Pearson’s r < 0.80
Validity
 Content validity + The target population considers all items in a questionnaire to be relevant AND considers the 
questionnaire to be complete
? No target population involvement
− The target population considers items in a questionnaire to be irrelevant OR considers the 
questionnaire to be incomplete
 Construct validity  
 Structural validity + Factors should explain at least 50% of the variance
? Explained variance not mentioned
− Factors explain <50% of the variance
 Hypothesis testing + (Correlation with an instrument measuring the same construct ⩾0.50 OR at least 75% of the 
results are in accordance with the hypotheses) AND correlation with related constructs is 
higher than with unrelated constructs
? Solely correlations determined with unrelated constructs
− Correlation with an instrument measuring the same construct <0.50 OR < 75% of the results 
are in accordance with the hypotheses OR correlation with related constructs is lower than 
with unrelated constructs
Responsiveness
 Responsiveness + (Correlation with an instrument measuring the same construct ⩾0.50 OR at least 75% of the 
results are in accordance with the hypotheses OR AUC ⩾0.70) AND correlation with related 
constructs is higher than with unrelated constructs
? Solely correlations determined with unrelated constructs
− Correlation with an instrument measuring the same construct <0.50 OR <75% of the results 
are in accordance with the hypotheses OR AUC <0.70 OR correlation with related constructs 
is lower than with unrelated constructs
Source: Terwee et al.18
MIC: minimal important change; SDC: smallest detectable change; LOA: limits of agreement; ICC: intraclass correlation coefficient; AUC: area under 
the curve; +: positive rating; ?: indeterminate; −: negative rating.
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Summary of results
The 41 articles included evaluated 22 HRQOL measures 
for use with children aged 0–18 years. Two papers dis-
cussed the results from the same study so were only ana-
lysed once.19,20 All included measures were originally 
developed to be completed in paper format. Five of the 
included measures were generic and 17 were disease spe-
cific. Of the disease-specific measures, three are for use 
with children with cardiac disease, three for cerebral palsy, 
six for cancer, one for brain tumours, three for epilepsy 
and one for neuromuscular disease. Four measures are 
child completed, four parent completed, thirteen have both 
parent and child forms and one measure had both child and 
clinician forms. Completion time ranged from 2 to 25 min, 
with the number of items ranging from 6 to 87. Recall time 
ranged from the current moment to 1 month. Table 3 shows 
a summary of the included studies, where data are missing 
it is because they are not available.
None of the studies included analysed measurement 
error or cross-cultural validity. One study reported on 
responsiveness and one on criterion validity.31 The 
COSMIN panel define criterion validity as ‘the degree to 
which the scores of an instrument are an adequate reflec-
tion of a gold standard’.16 As outcome measures focus on 
perceptions that may by subjective, they usually lack a 
gold standard. The only exception to this would be if a 
shorter version of a measure was developed from an 
already validated longer one, where the longer version 
could be considered to be the gold standard. Therefore, the 
results of this analysis of criterion validity have not been 
included here.
The methodological quality of included studies is 
shown in Table 4 and ranged from poor to excellent. 
Table 5 shows the synthesis of results per outcome meas-
ure with levels of evidence of quality. This ranged from 
strong to unknown.
Figure 1. PRISMA flow chart.
Source: From Moher et al.8
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Table 4. Methodological quality of included measures.
Study Internal 
consistency
Reliability Measurement 
error
Content 
validity
Structural 
validity
Hypothesis 
testing
Responsiveness Cross-cultural 
validity
CHQ-PF50
 Drotar et al.19 Fair  
 Ferro et al.20 Good  
 McCullough et al.21 Good Good  
 Wake et al.22 Poor  
ConQOL
 Macran et al.23 Poor Fair Excellent Fair  
CP-QOL
 Waters et al.24 Poor Fair Poor Fair  
CP-QOL Teen
 Davis et al.25 Poor Fair Poor Good  
DISABKIDS
 Petersen et al.26 Fair Excellent Fair  
  Ravens-Sieberer 
et al.27/Schmidt et al.28
Fair Fair Excellent Fair Fair  
 Simeoni et al.29 Fair Fair Fair Fair  
DISABKIDS Smiley
 Chaplin et al.30 Poor Excellent Poor  
GEOSYP
 Townshend et al.31 Poor Poor Fair Fair  
HRQOL in children with epilepsy
 Ronen et al.32 Fair Fair Fair  
KIDSCREEN-52
 Erhart et al.33 Fair  
MSAS 7–12
 Collins et al.34 Fair Fair Fair  
MSAS 10–18
 Collins et al.35 Fair Fair Fair Fair Fair  
PCQL-32
 Varni et al.36 Poor Good Fair  
 Seid et al.37 Poor Good  
Ped Cardiac QOL Inventory
 Marino et al.38 Good Good Fair  
 Marino et al.39 Fair Fair  
 Wray et al.40 Fair Fair  
Ped Oncology QOL Scale
 Goodwin et al.42 Fair Poor Good Fair Fair  
PedsQL™ Generic Core Scale (child)
 Varni et al.42 Fair Fair  
 Varni et al.43 Good Good  
 Varni et al.44 Poor Fair Good  
 Varni et al.45 Fair  
 Varni et al.46 (parent)  
 Amin et al.47 Poor Fair  
 Huang et al.7 Good Excellent Poor  
 Varni et al.42 Fair Fair  
 Varni et al.43 Good Good  
 Varni et al.48 Good Good  
PedsQL™ Brain Tumour Module
 Palmer et al.49 Poor Fair  
PedsQL™ Cancer Module
 Varni et al.50 Poor Fair  
PedsQL™ Cardiac Module
 Uzark et al.51 Fair Excellent  
PedsQL™ Cerebral Palsy Module
 Varni et al.52 Poor Fair  
(Continued)
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Study Internal 
consistency
Reliability Measurement 
error
Content 
validity
Structural 
validity
Hypothesis 
testing
Responsiveness Cross-cultural 
validity
PedsQL™ Neuromuscular Module
 Davis et al.54 Poor Poor Poor  
 Dunaway et al.55 Poor  
 Iannaccone et al.53 Poor Fair Good Fair  
Quality of Life in Childhood Epilepsy Questionnaire
 Sabaz et al.56 Poor Fair Poor  
 Sabaz et al.57 Poor Poor  
Royal Marsden Ped Oncology QOL Questionnaire
 Watson et al.58 Poor Fair Poor  
aTwo papers reporting on the same data.
Table 4. (Continued)
Table 5. Data synthesis.
Questionnaire Internal 
consistency
Reliability Measurement 
error
Content 
validity
Structural 
validity
Hypothesis 
testing
Responsiveness Cross-cultural 
validity
CHQ-PF50 ± ±
ConQOL ? + +++ ±  
CQOL ? ? ?  
CP-QOL ? + ? +  
CP-QOL Teen ? + (child)
− (parent)
? −  
DISABKIDS ++ + +++ ++ ++  
DISABKIDS SMILEY ? +++ ?  
GEOSYP ? ? + +  
HRQOL epilepsy + + +  
KIDSCREEN-52 +  
MSAS 7–12 + + +  
MSAS 10–18 + ± + + +  
PCQL-32 ? ++ ++  
Pediatric cardiac quality of life 
inventory
++ ++ ++ ++  
Pediatric oncology quality of 
life scale
+ ? ++ + +  
PedsQL™ Generic +++ ++ ++  
PedsQL™ Brain tumour module ? +  
PedsQL™ Cancer module ? +  
PedsQL™ Cardiac module + +++  
PedsQL™ CP module ? +  
PedsQL™ Neuromuscular 
module
? + (child)
− (parent)
++ +  
Quality of Life in Childhood 
Epilepsy
? + ?  
Royal Marsden Paediatric 
oncology quality of life 
questionnaire
? + ?  
+++ or – – –: strong evidence for positive/negative results; ++ or – –: moderate evidence for negative/positive results; ±: conflicting evidence;  
?: unknown due to poor methodological quality.
Internal consistency was tested in 34 of the included 
studies. However, 40% of these lacked a check of the uni-
dimensionality of the scale, leading to a score of poor for 
methodological quality.59
Test–retest reliability testing was carried out in 14 of the 
studies. In all, 38% of studies had a sample size of at least 
100 which is needed for an excellent quality score.11 Only 
one study described how missing items were handled. If 
not handled appropriately, this could lead to over or under-
estimation of reliability.
Content validity testing was carried out in 13 of the 
included studies. The main flaws in the methodology of 
content validity testing were inclusion of only small num-
bers in focus groups, pilot studies and cognitive testing 
and not involving children, parents and professionals in 
the process. Ideally, all should be included to make sure 
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the items are relevant and ensure no important items are 
missing.
Structural validity can be assessed by factor analysis or 
IRT tests for dimensionality.12 Structural validity was 
assessed in 14 of the studies and generally there was appro-
priate use of confirmatory or exploratory factor analysis. 
In order to carry out structural validity testing, a sample 
size of 5–7 times the number of items (and greater than 
100) is recommended.11 This was achieved in 93% of the 
studies. Lack of description of missing items and how they 
were handled let down 64% of the studies.
Only one study analysed responsiveness.58 No correla-
tions between change scores were calculated in the 
included study; a paired t-test was carried out instead, thus 
the methodology for this was scored as poor. Sample size 
was also inadequate and there was no description of how 
missing items were handled.
Discussion
Main findings
To the authors’ knowledge, this is the first systematic 
review of outcome measures that could potentially be used 
in PPC. The aim of this review was to examine the feasi-
bility of use of measures, as well as the methodological 
quality of analysis of measurement properties of included 
studies. The review identified 22 measures, 5 generic and 
17 disease specific, which could potentially be useful. The 
disease-specific measures included those for use in chil-
dren with cardiac disease,23,38–40,51 cerebral palsy,24,27,52 
cancer,34–37,41,50,58 brain tumours,49 epilepsy31,32,56 and neu-
romuscular disease.53–55 All measures were initially devel-
oped in the English language. None of the measures were 
developed for use in CYP receiving palliative care. All 
were developed to be completed in paper format, predomi-
nantly by the CYP and/or their parent.
The PedsQL™ Generic Core Scale was the most widely 
analysed in terms of its measurement properties. It is 
unique because it contains a generic core scale and various 
disease-specific modules that can be administered along-
side the core scale.
Quality of assessment of measurement 
properties
None of the studies on measurement properties in this 
review achieved a score of fair methodological quality or 
higher in all characteristics. Most of the studies show posi-
tive results (except parent test–retest reliability in two stud-
ies and hypothesis testing in one, see Table 5). Evidence is 
mainly limited and at least half the information on meas-
urement properties per questionnaire is missing. The meth-
odological quality of the included studies varied greatly 
and therefore results should be treated cautiously.
Internal consistency, reliability, content validity and 
hypothesis testing were widely assessed in the papers. 
Only one study analysed responsiveness.58 It is imperative 
that any measure used to assess HRQOL is responsive to 
change, particularly in PPC, where a child’s condition can 
change frequently and sometimes rapidly. Measurement 
error was not tested in any of the included studies. With the 
same data, both reliability and measurement error can be 
calculated.12 In all, 14 of the 22 included studies assessed 
reliability, thereby measurement error could easily have 
been reported.
Feasibility of use of included measures
In adult palliative care, there are concerns regarding the 
use and relevance of outcome measures.60 These concerns 
include the method of administration and whether the 
patient, carer or professional completes the measure.60 
These concerns are probably just as applicable to PPC. 
Many children requiring palliative care services are non-
verbal or too unwell to self-complete the tools and thereby 
rely on the reports of their carers and/or professionals. The 
method of administration of a measure is also important. 
Different modes of administration may be appropriate 
depending on the type and stage of a CYP illness. The 
PedsQL™ is the only measure included in this review that 
has been validated across different modes of administra-
tion.48 Multi-group confirmatory factor analysis was per-
formed showing strong factorial invariance across three 
modes of administration groups (mail, in-person and tele-
phone survey). With widespread mobile technology now 
available, new ways of collecting data, such as online or 
via an app, should be considered as these may be more 
acceptable to CYP and their carers, as well as being easier 
to access.
Within PPC, as in adult palliative care, there is a debate 
as to who should complete outcome measures. Most chil-
dren with life-limiting and life-threatening illnesses are 
cared for at home by their parents, so a clinician completed 
measure is not always ideal. HRQOL is generally under-
stood as a latent, not directly observable construct, and 
contains the perceptions and evaluation of one’s life from 
the subjective view of the individual, as well as the indi-
vidual’s subjective well-being and affective mood.61 
Wherever possible, the child’s self-report of HRQOL 
should be sought. Within this population, some children 
will be too young or too unwell to complete a measure and 
a parent/proxy completed measure will need to be used. A 
total of 19 of the 22 measures included in this review con-
tain parent reports. Of those studies that looked at correla-
tion between child and parent scores, three found moderate 
correlation between parent and child scores.37,38,49 One 
study showed poor correlation in the psychological and 
emotional subscales.52 These results support those of pre-
vious studies that show a higher correlation for observable 
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constructs, such as physical aspects, and a lower correla-
tion for non-observable constructs such as emotional prob-
lems between parents and children.62
Recall period in the included studies ranged from the 
current moment to 1 month. Research has shown that chil-
dren as young as 8 years can use a 4-week recall period with 
accuracy.63 However, HRQOL measures with shorter recall 
periods are likely to elicit more accurate responses.64 Most 
of the disease-specific measures had shorter recall periods, 
which is more appropriate as there can be variation in 
symptoms over a longer period in many cases. Children 
with palliative care needs often have frequently changing 
symptoms which can affect their HRQOL so a measure 
with a shorter recall period may be more appropriate.
There were a variety of response options used in the 
included measures. The most common method was a 
Likert scale and response options ranged from 3 to 9 
points. It has been recommended that fewer responses 
should be employed for younger children as they tend to 
choose responses at the extremes.63 There is also little evi-
dence showing that young children can effectively respond 
to Likert scales.64 The completion time (when reported) 
for measures was between 2 and 25 minutes. Shorter 
measures are preferable in PPC as children will fatigue 
easily. Shorter parent-completed measures are also prefer-
able as parents will already have the burden of caring for 
their sick child.
HRQOL instruments may be either generic or disease 
specific.7 Generic measures are useful for comparing gen-
eral quality of life across different populations. These 
measures are used with healthy children so are more likely 
to have been validated based on large samples but may 
lack sensitivity in sick CYP. Disease-specific quality-of-
life instruments, on the other hand, are used to compare 
quality of life within a given condition. Disease-specific 
measures are assumed to be more sensitive to the implica-
tions of different illnesses and may be more appropriate 
for evaluating interventions or different treatments within 
CYP with the same illness.62 The drawback of this is that it 
is not possible to compare HRQOL across groups of CYP 
with different illnesses, which is essential for a discipline 
as wide and varied as PPC. The measures included in this 
study contain varying numbers of domains but all covered 
the constructs of HRQOL (physical, emotional and social). 
Some of the domains included in the generic HRQOL 
measures may not be relevant for the PPC population. For 
example, domains such as school environment may be 
irrelevant for a child near the end of life. One of the 
included studies aimed to validate the PedsQL™ in chil-
dren with life-limiting illnesses.7 Confirmatory factor 
analysis did not support the construct validity of the 
PedsQL™ in this group of children, implying that the 
hypothesized HRQOL structures between children with 
life-limiting illnesses and other populations may be differ-
ent. Most of the generic measures included in this review 
do not capture the impact of life-limiting illness on daily 
functioning and well-being.
Implications for research
As discussed above, it is questionable whether any of the 
included generic measures, such as the PedsQL™ and 
Child Health Questionnaire, would be valid in the PPC 
population without adaptation, due to concerns regard-
ing construct validity. The Memorial Symptom 
Assessment Scales (MSAS) for children could potentially 
be useful in PPC.34,35 Although they capture many of the 
domains of PPC, they would need testing for validity 
and reliability in the population. It is unlikely that with-
out adaptation, they would be useful in a non-cancer 
population as there is a question about hair-loss, which is 
unique to this group of children. The methodological 
quality of studies on the MSAS was fair throughout. 
Other disease-specific measures included in this review 
may be useful in PPC. For example, the PedsQL™ 
Neuromuscular module was designed for use in children 
with spinal muscular atrophy and muscular dystrophy 
which are both life-limiting conditions.53,54,57 However, 
within the three studies included in this review, the 
majority of assessment of its psychometric properties 
was scored as fair or poor. It is unlikely that any of the 
included measures would have acceptable measurement 
properties in the entire range of children receiving PPC 
services, as the population is so diverse.
None of the measures included in this review meet all 
the requirements for use in the PPC population. The 
generic measures do not capture the full impact of living 
with a life-limiting illness and often have recall periods 
that could be considered too long in a child whose condi-
tion may be changing frequently. The disease-specific 
measures contain domains that are only relevant to CYP 
with specific illnesses so could not be used to compare 
children with different conditions. One potential solution 
to this is to revise an existing instrument. An alternative is 
to develop a completely new measure. It is questionable 
whether by using either method it will be possible to 
develop a HRQOL outcome measure for a population as 
diverse as PPC. Children have many different types of ill-
nesses, some of which are extremely rare and each illness 
comes with its own set of physical, psychological and 
emotional needs. All items in a measure may not be equally 
useful for children with different life-limiting conditions. 
Findings from other studies have suggested that static 
models (all items are administered to all subjects) will 
increase measurement error and decrease precision.7  
The use of IRT along with computerized adaptive testing 
(CAT) may better assess HRQOL for this population.7 
Alternatively, using individualized measurement tools 
rather than standardized ones may be a solution.7 The 
Schedule for the Evaluation of Individual Quality of Life 
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(SEIQoL) has been shown to be valid and reliable in a 
population of terminally ill adult cancer patients.65
Two relatively new concepts in healthcare, patient 
reported experience measures (PREMs) and patient-cen-
tred outcome measures (PCOMS), may also be beneficial 
to CYP and their families receiving palliative care ser-
vices, but more research in this area is required. PCOMs 
involve putting patients and their families/carers at the 
heart of deciding which goals are most valuable for an 
individual, rather than clinicians deciding what is best.66 
PREMs measure patient experience with the goal of 
improving services. It is desirable to combine measures of 
experience with measures of outcome to obtain a rounded 
view of the quality of care.67
Strengths and limitations
This review has several strengths. First of all, this is the 
first review the authors are aware of which examines the 
measurement properties and feasibility of using already 
developed outcome measures in the PPC population. 
The review was comprehensive, the search strategy 
found more than 3000 articles for potential inclusion 
and over 40 papers were systematically appraised and 
compared.
This review also has several limitations. First, it is 
never possible to be sure that all relevant studies have been 
identified. The COSMIN checklist is based on expert 
group opinion. The inter-rater agreement of the COSMIN 
checklist is adequate. The inter-rater reliability for many 
COSMIN items is poor, which has been suggested to be 
due to interpretation of checklist items.68 Selected articles 
were restricted to English language. Finally, it was some-
times not clear if certain criteria on the COSMIN checklist 
were not performed or not reported on. Therefore, it was 
not possible to distinguish between poor reporting and 
poor quality.
Conclusion
Although there is no ‘ideal’ HRQOL measure for use in 
PPC at the moment, it is important to continue developing 
and researching measures in this area.
Outcome measurement in PPC is rarely carried out and 
as of yet there are no specific HRQOL measures for use in 
this population. In light of new developments in the field 
of PREMS and PCOMs, it may be desirable to develop a 
combination of measures that are able to measure out-
comes that are important to the individual child and family, 
as well as measuring their satisfaction of the experience of 
the services that deliver care. The purpose of measuring 
quality of life and outcomes in CYP receiving PPC is 
potentially fourfold: to improve clinical care, to audit and 
evaluate services, for research purposes and to inform 
commissioners and secure funding.60
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